Resolution of the experts’ council “perspective possibilities of using GRS drug in therapeutic practice”

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Current resolution represents the key characteristics and peculiarities of an innovative drug development – a domestic pharmaceutical product for the treatment of a wide range of cardiovascular diseases, designated by GRS code. Mechanisms of action and spectrum of effects, results of clinical trials (CTs) of phases I and II, prospects for using the drug in therapeutic practice, as well as the main and additional directions of the planned phase III CTs are considered.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Martynov

Russian University of Medicine of the Ministry of Healthcare of Russia

Хат алмасуға жауапты Автор.
Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, academician of RAS, president of the Russian Scientific Medical Society of Internal Medicine (RSMSIM), professor of the Department of hospital therapy No. 1 of the Faculty of general medicine, Members of the Experts’ Council

Ресей, Moscow

O. Barbarash

Research Institute of Complex Problems of Cardiovascular Diseases of the Ministry of Science and Higher Education of the Russian Federation

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, academician of RAS, director, head of the Department of cardiology and cardiovascular surgery of Kemerovo State Medical University of the Ministry of Healthcare of Russia, vice-president of the Russian Society of Cardiology, chief cardiologist of the Siberian Federal District, Honored Scientist of the Russian Federation, Members of the Experts’ Council

Ресей, Kemerovo

Zh. Kobalava

Medical Institute of RUDN University

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, vice-president of RSMSIM, head of the Department of internal medicine with courses of cardiology and functional diagnostics named after academician V.S. Moiseev, Members of the Experts’ Council

Ресей, Moscow

A. Malyavin

Faculty of general medicine of Russian University of Medicine of the Ministry of Healthcare of Russia

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, general secretary of RSMSIM, chief external expert – pulmonologist of the Ministry of Healthcare of Russia in the Central Federal District, professor of the Department of phthisiology and pulmonology, Members of the Experts’ Council

Ресей, Moscow

A. Boshchenko

Tomsk National Research Medical Center of the Russian Academy of Sciences

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), associate professor, deputy director for research work of the Research Institute of Cardiology, Members of the Experts’ Council

Ресей, Tomsk

A. Vengerovskii

Siberian State Medical University of the Ministry of Healthcare of Russia

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, professor of the Department of pharmacology, Honorary Figure of Russian Higher Education, Members of the Experts’ Council

Ресей, Tomsk

D. Zateyshchikov

Central State Medical Academy of the Administration of the President of the Russian Federation; City Clinical Hospital No. 51 of the Department of Healthcare of Moscow

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, head of the Department of therapy, cardiology and functional diagnostics with a course of nephrology, head of the Primary Vascular Department, Members of the Experts’ Council

Ресей, Moscow; Moscow

A. Chesnikova

Rostov State Medical University of the Ministry of Healthcare of Russia

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, member of the presidium of RSMSIM, authorized representative of RSMSIM in the Southern Federal District, head of the Department of internal medicine No. 1, chief external expert-therapist of the Southern Federal District, Members of the Experts’ Council

Ресей, Rostov-on-Don

S. Yakushin

Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, head of the Department of hospital therapy with a course of medical and social expertise, Members of the Experts’ Council

 

Ресей, Ryazan

V. Kashtalap

Kemerovo State Medical University of the Ministry of Healthcare of Russia; Research Institute of Complex Problems of Cardiovascular Diseases of the Ministry of Science and Higher Education of the Russian Federation

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, professor of the Department of cardiology and cardiovascular surgery, head of the Department of clinical cardiology, chief investigator in clinical trials of the medicinal product Granik®, Members of the Experts’ Council

Ресей, Kemerovo; Kemerovo

V. Khazanov

IFAR group of companies

Email: info@rnmot.org

MD, Dr. Sci. (Medicine), professor, chairman of the board of directors of the IFAR group of companies, developer of the medicinal product Granik®, Members of the Experts’ Council

Ресей, Tomsk

V. Bykov

IFAR group of companies

Email: info@rnmot.org

MD, PhD, (Medicine), head of Department of preclinical research of the IFAR group of companies, developer of the medicinal product Granik®, Members of the Experts’ Council

Ресей, Tomsk

V. Larchenkо

IFAR group of companies

Email: info@rnmot.org

MD, PhD (Medicine), head of the Department of clinical research of the IFAR group of companies, developer of the medicinal product Granik®, Members of the Experts’ Council

Ресей, Tomsk

Әдебиет тізімі

  1. Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Врач скорой помощи. 2006; (1): 51–59. [Vovk E.I., Naumov A.V., Chudakov S.Yu. An effective and safe antiplatelet therapy in general practice. Vrach skoroy pomoshchi = Ambulance Doctor. 2006; (1): 51–59 (In Russ.)].
  2. Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения с позиций доказательной медицины. 2-е изд. М.: ООО «Медицинское информационное агентство». 2009; 224 с. [Suslina Z.A., Tanashyan M.M., Domashenko M.A. Antithrombotic therapy of ischemic disorders of cerebral circulation. 2nd ed. Moscow: Meditsinskoe informatsionnoe agenstvo = Medical News Agency. 2009; 224 pp. (In Russ.)].
  3. ISBN: 978-5-8948-1710-1. EDN: TOMWDJ.
  4. Кашталап В.В., Седых Д.Ю. Эффективная антитромботическая терапия при мультифокальном атеросклерозе. РМЖ. Медицинское обозрение. 2024; 8(1): 42–47. [Kashtalap V.V., Sedykh D.Yu. Effective antithrombotic therapy in multifocal atherosclerosis. Russkiy meditsisnkiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2024; 8(1): 42–47 (In Russ.)]. https://doi.org/10.32364/2587-6821-2024-8-1-7. EDN: GZNPBF.
  5. Айнетдинова Д.Х., Удовиченко А.Е., Сулимов В.А. Роль антитромбоцитарной терапии в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Эффективная фармакотерапия в кардиологии и ангиологии. 2007; (6): 38–42. [Aynetdinova D.Kh., Udovichenko A.E., Sulimov V.A. The role of antiplatelet therapy in primary and secondary prevention of cardiovascular diseases. Effektivnaya farmakoterapiya v kardiologii i angiologii = Effective Pharmacotherapy in Cardiology and Angiology. 2007; (6): 38–42 (In Russ.)]. EDN: XTMETJ.
  6. Кашталап В.В. Медикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения). Российский кардиологический журнал. 2022; 27(11): 68–75. [Kashtalap V.V. Therapy for hypertension and dyslipidemia: Potential of Lipertans (on the example of a clinical observation). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27(11): 68–75]. https://doi.org/10.15829/1560-4071-2022-5285. EDN: DXSNGE.
  7. Stalker T.J., Newman D.K., Ma P. et al. Platelet signaling. Handb Exp Pharmacol. 2012; (210): 59–85. https://doi.org/10.1007/978-3-642-29423-5_3. PMID: 22918727. PMCID: PMC4785017.
  8. Sandner P., Zimmer D.P., Milne G.T. et al. Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol. 2021; (264): 355–94. https://doi.org/10.1007/164_2018_197. PMID: 30689085.
  9. Граник В.Г., Рябова С.Ю., Паршин В.А., Михайлова Л.А., Григорьев Н.Б. (ООО «Протон»). Патент Российской Федерации RU 2483066. МПК C07D413/06. Новое антитромботическое и антиатеросклеротическое средство и способ его получения (варианты). Заявлено 08.11.2011, опубл. 27.05.2013. [Granik V.G., Ryabova S.Yu., Parshin V.A., Mikhailova L.A., Grigoriev N.B. (Proton LLC). Patent of the Russian Federation RU 2483066. IPC C07D413/06. New antithrombotic and antiatherosclerotic agent and method of its preparation (options). Announced 11/08/2011, publ. 05/27/2013 (In Russ.)].
  10. Быков В.В., Смольякова В.И., Чернышева Г.А. с соавт. Влияние нового антитромботического средства GRS – стимулятора растворимой гуанилатциклазы на эндотелиальную дисфункцию у крыс после инфаркта миокарда. Бюллетень экспериментальной биологии и медицины. 2021; 172(12): 707–710. [Bykov V.V., Smol’yakova V.I., Chernysheva G.A. et al. Effects of a new antithrombotic drug GRS, a soluble guanylate cyclase stimulator, on endothelial dysfunction in rats with myocardial infarction. Byulleten’ eksperimental’noj biologii i mediciny = Bulletin of Experimental Biology and Medicine. 2021; 172(12): 707–710 (In Russ.)]. https://doi.org/10.47056/0365-9615-2021-172-12-707-710. EDN: ASERIY.
  11. Bykov V.V., Birulina Yu.G., Nosarev A.V. et al. Antihypertensive effects of a soluble guanylate cyclase stimulator. Bull Exp Biol Med. 2022; 174(1): 41–45. https://doi.org/10.1007/s10517-022-05643-8. PMID: 36437315.
  12. Быков В.В., Чернышева Г.А., Смольякова В.И. с соавт. Антиагрегантная активность нового производного индолинона. Экспериментальная и клиническая фармакология. 2019; 82(7): 10–13. [Bykov V.V., Chernysheva G.A., Smol’yakova V.I. et al. Antiplatelet activity of a new indolinone derivative. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2019; 82(7): 10–13 (In Russ.)]. https://doi.org/10.30906/0869-2092-2019-82-7-10-13. EDN: KAYKAT.
  13. Быков В.В., Быкова А.В., Станкевич С.А. с соавт. Фармакологические эффекты нового стимулятора растворимой гуанилатциклазы при экспериментальной легочной артериальной гипертензии. Бюллетень сибирской медицины. 2023; 22(1): 14–22. [Bykov V.V., Bykova A.V., Stankevich S.A. et al. Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2023; 22(1): 14–22 (In Russ.)]. https://doi.org/10.20538/1682-0363-2023-1-14-22. EDN: KTUVCO.
  14. Bykov V.V., Bykova A.V., Dzyuman A.N. et al. Anti-atherosclerotic action of a new stimulator of soluble guanylate cyclase in an experiment. Bull Exp Biol Med. 2022; 174(3): 333–36. https://doi.org/10.1007/s10517-023-05703-7. PMID: 36723753.
  15. Быков В.В., Быкова А.В., Алиев О.И. с соавт. Влияние нового стимулятора растворимой гуанилатциклазы на агрегацию тромбоцитов и функции сосудистого эндотелия при экспериментальном ишемическом инсульте на фоне артериальной гипертензии. Артериальная гипертензия. 2022; 28(6): 710–717. [Bykov V.V., Bykova A.V., Aliev O.I. et al. Influence of a new stimulator of soluble guanylate cyclase on platelet aggregation and vascular endothelial function in experimental ischemic stroke against the background of arterial hypertension. Arterial’naya gipertenziya = Arterial Hypertension. 2022; 28(6): 710–717 (In Russ.)]. https://doi.org/10.18705/1607-419X-2022-28-6-710-717. EDN: CMZCLN.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2024

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>